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Latent transforming growth factor -binding protein
1 (LTBP-1) targets latent complexes of transforming
growth factor  to the extracellular matrix, where the
latent cytokine is subsequently activated by several dif-
ferent mechanisms. Fibrillins are extracellular matrix
macromolecules whose primary function is architectur-
al: fibrillins assemble into ultrastructurally distinct mi-
crofibrils that are ubiquitous in the connective tissue
space. LTBPs and fibrillins are highly homologous mol-
ecules, and colocalization in the matrix of cultured cells
has been reported. To address whether LTBP-1 func-
tions architecturally like fibrillins, microfibrils were ex-
tracted from tissues and analyzed immunochemically.
In addition, binding studies were conducted to deter-
mine whether LTBP-1 interacts with fibrillins. LTBP-1
was not detected in extracted beaded-string microfi-
brils, suggesting that LTBP-1 is not an integral struc-
tural component of microfibrils. However, binding stud-
ies demonstrated interactions between LTBP-1 and
fibrillins. The binding site was within three domains of
the LTBP-1 C terminus, and in fibrillin-1 the site was
defined within four domains near the N terminus. Im-
munolocalization data were consistent with the hypoth-
esis that LTBP-1 is a fibrillin-associated protein present
in certain tissues but not in others. In tissues where
LTBP-1 is not expressed, LTBP-4 may substitute for
LTBP-1, because the C-terminal end of LTBP-4 binds
equally well to fibrillin. A model depicting the relation-
ship between LTBP-1 and fibrillin microfibrils is
proposed.
The fibrillins and latent transforming growth factor -bind-
ing proteins (LTBPs)1 are members of a family of homologous
molecules. The fibrillins and LTBPs contain multiple calcium-
binding epidermal growth factor-like modules interspersed by
a domain module (the 8-Cys or TB module), so far found only in
these two proteins. Fibrillin-1 (1–4) and fibrillin-2 (5, 6) share
a highly similar overall structure. Both molecules are of equiv-
alent size (350 kDa) and domain organization. In contrast,
LTBP-1 (7, 8), LTBP-2 (9), LTBP-3 (10), and LTBP-4 (11, 12)
are each smaller than the fibrillins and variable in size.
Extensive immunolocalization data combined with struc-
tural analyses of the fibrillin-1 monomer and fibrillin-contain-
ing microfibrils (1, 13–15) have established that fibrillin-1 is a
major structural component of connective tissue microfibrils.
In addition, genetic evidence in humans (16, 17) and mice (18,
19) has confirmed that fibrillin-1 performs a significant role in
the maintenance of microfibrils and elastic fibers.
Fibrillin-2, whose structure is predicted to be highly similar
to fibrillin-1, has also been immunolocalized to microfibrils
(20). However, in contrast to fibrillin-1, the contribution of
fibrillin-2 to microfibril structure is temporally and spatially
restricted. In situ hybridization studies in mice indicated that
expression of the fbn2 gene is most prominent in the early
developing fetus (20). Genetic evidence in humans (5, 21) sug-
gests that fibrillin-2 plays a more restricted role in the main-
tenance of microfibrils and elastic fibers in postnatal connec-
tive tissues. Recent immunolocalization studies demonstrate a
ubiquitous early distribution of fibrillin-2 in fetal tissues fol-
lowed by a restricted distribution in postnatal tissues (22).
Mice produced by gene targeting experiments recapitulate the
features (contractures of large and small joints) of the human
disease congenital contractural arachnodactyly caused by mu-
tations in fibrillin-2 (23). In addition, fibrillin-2 null mice re-
vealed an unexpected role for fibrillin-2 in limb patterning,
because the mutant animals display syndactyly (23).
LTBP-1 forms a complex with latent TGF- and targets it to
the extracellular matrix (7). Latent TGF- consists of the ma-
ture growth factor plus the TGF- propeptide, also known as
the latency associated peptide (LAP). LAP binds to TGF- by
noncovalent interactions, and the association of LAP with
TGF- prevents the growth factor from binding to its receptor.
During the secretory process, CR3, the second 8-Cys module, in
LTBP-1 becomes disulfide-linked to the latency associated
propeptide (LAP) of TGF- (24, 25). The processed TGF- re-
mains noncovalently bound within this complex of LAP and
LTBP. Studies of 8-Cys modules from fibrillin-1 indicate that
the 8 conserved cysteine residues in this module form 4 intra-
chain disulfide bonds (15). The solution structure of one 8-Cys
module from fibrillin-1 has been determined (26), indicating
the position of disulfide bonds. The structure of the 8-Cys
module in LTBP-1, which is disulfide-linked and complexed
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with latent TGF-, is not yet known. However, based upon the
conformation of the fibrillin 8-Cys motif, binding of LTBP-1 to
LAP has been proposed to occur through Cys4 and Cys7 or Cys2
and Cys6 (26). LTBP-3 and LTBP-4, but not LTBP-2, also
interact with LAP (27).
LTBP-1 becomes immobilized into the extracellular matrix of
tissue culture cells in a covalent manner involving tissue trans-
glutaminase-mediated cross-linking of a region in the N-termi-
nal sequence of LTBP to an undefined matrix protein (28). In
tissue culture, LTBP-1 colocalizes with both fibronectin and
fibrillin-1 (29, 30). LTBP-1 has been immunolocalized to fibril-
lin-containing microfibrils in the skin (31) and bone (30, 32)
and to microfibrillar structures in the heart (33). LTBP-2 has
also been immunolocalized to fibrillin-containing microfibrils
(34) and exogenous LTBP-2 can be incorporated into the extra-
cellular matrix by fibroblasts (35). Studies of mRNA have in-
dicated that LTBPs are differentially expressed in various tis-
sues. However, surveys of the distribution of LTBP-1 protein in
tissues have not been conducted. Moreover, the relationship
between LTBPs and fibrillins within microfibril structures is
not understood. The investigations presented here were under-
taken to determine whether LTBP-1 is present in extracted
fibrillin microfibrils, whether LTBP-1 and fibrillin bind to each
other, and if so, which regions of the two proteins interact.
EXPERIMENTAL PROCEDURES
Production of Recombinant Polypeptides—Recombinant human
fibrillin polypeptides used in these investigations have been previously
described and characterized (15, 22, 36–38). These are depicted sche-
matically in Fig. 1B. All recombinant fibrillin polypeptides were ex-
pressed using 293 human embryonic kidney cells.
Full-length recombinant human LTBP-1 was expressed in insect
cells as previously described (25). To make the expression construct
rL1N, coding for Asn21 to Ile629 of LTBP-1, clone pACUW-51 was am-
plified with sense primer LTBP-1-1S (5-CTGCTAGCAAACCACACTG-
GCCGCATCAAG-3) introducing a NheI restriction site at the 5 end,
and antisense primer LTBP-1-1AS (5-CTCGAGTCAATGATGATGAT-
GATGATGTATGCAGTTAGTACCCTCCTC-3), introducing the se-
quence for 6 histidine residues, a stop codon, and a XhoI restriction site
at the 3 end. The resulting NheI-XhoI fragment was subcloned into the
expression vector pCEP/2III4, which contains the sequence for the
BM40/SPARC signal peptide (39). To make the expression construct
rL1M, coding for Asp588 to Phe1139 of LTBP-1, template was amplified
with LTBP-1-2S (5-CTGCTAGCAGATATTGATGAGTGTACTCAGCA-
GGTC-3) and LTBP-1-2AS (5-CTCTCGAGTCAATGATGATGATGAT-
GATGAAAGCACTGCAGTTTCACAGG-3). For rL1C, coding for
Asp1097 to Glu1394, the primer set LTBP-1-3S, (5-CTGCTAGCAGATGC-
AGATGAATGCCTACTTTTTG-3) and LTBP-1-3AS (5-CTCTCGAGTC-
AATGATGATGATGATGATGCTCCAGGTCACTACTGTCTTTCTC-3)
was used. rL1K, coding for Arg1181 to Glu1394, was amplified with LTBP-
1-29S (5-AGCTGCTAGCACGACCGGCTGAGTCAAACGAAC-3) and
LTBP-1-3AS. The correct in-frame insertion of all constructs and the
sequence of PCR amplified products were confirmed by sequence analysis
using a DNA sequencer (Applied Biosystems 373A).
The cDNA that was used to obtain expression construct rL4K
(Ser1301-Ala1587 of LTBP-4) was derived from normal human dermal
fibroblast RNA by reverse transcriptase-PCR. PCR amplification of the
cDNA used sense primer rL4K-S (5-GATCGCTAGCATCCAACGAGA-
GCCAGAGCC-3) and antisense primer rL4K-AS (5-GAGTCTC-
GAGCTCAGTGATGGTGATGGTGATGGGCCCGGGGCCGTGCGG-3),
which introduced, respectively, a 5 NheI restriction site and a 3
sequence for 6 histidine residues, a stop codon, and an XhoI site. An
894-bp NheI-XhoI-restricted insert was subcloned into the expression
vector pCEP4/2III4. The entire insert of the resulting construct, des-
ignated pCEPSP-rL4K, was then verified by DNA sequencing.
Mouse LTBP-3 specific sense primer L3-4F (5-CCAGAAGGAGAG-
TCTGTGGC-3) and antisense primer L3-4R (5-TGTGGGCACTTGT-
GACACTT-3) were designed based on the published sequence (10) and
used in reverse transcriptase-PCR to amplify a fragment of mouse
LTBP-3 cDNA (nucleotide 460–902, with the A in the translation start
codon ATG designated as 1) from RNA extracted from 2T3 mouse
osteoblast cells. This fragment was used as a probe for screening of a
mouse heart cDNA library (Clontech). Several full-length LTBP-3
cDNA clones were isolated and cloned as EcoRI-EcoRI fragments into
pBluescript SK (Stratagene) vector. Several errors were found in the
original sequence by analyzing these cDNA clones.2 To make the ex-
pression vector rL3K, encoding the region from the beginning of CR4 to
the COOH terminus, a fragment of the cDNA was amplified by PCR
using sense primer L3CR4C-S (5-CGGCTAGCCCCAAAGAGACGTG-
AAGTG-3) and antisense primer L3CR4CAS (5-CCGCTCGAGTCA-
GTGGTGGTGGTGGTGG-CGGCGGCGCTGAGGCAC-3), introducing
an NheI site at the 5 end and the sequence for 6 histidine residues, a
stop codon, and an XhoI site at the 3 end. The NheI-XhoI fragment was
subcloned into the expression vector pCEP4/2III4. The correct orien-
tation of the insert and the sequence of the PCR amplified fragment
were verified by DNA sequencing.
Schematic representations of the LTBP constructs used for these
studies are shown in Fig. 1A. For stable episomal expression, 293 EBNA
cells (Invitrogen) were transfected with the expression plasmids by a
calcium phosphate precipitation method as described previously (40).
Purification of the recombinant peptides was accomplished using che-
2 Y. Chen, unpublished result.
FIG. 1. Schematic representations
of the recombinant polypeptides
used in this study. A, LTBP-1, LTBP-3,
and LTBP-4 polypeptides. B, fibrillin-1
and fibrillin-2 polypeptides.
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lating chromatography (HiTrap chelating, Amersham Biosciences) (15)
followed by molecular sieve chromatography, using Superose 6 (Amer-
sham Biosciences) in 50 mM Tris-HCl, pH 7.5, 0.15 M NaCl (TBS) for
rL1M and rL1C or 50 mM Tris-HCl, pH 7.5, 1 M NaCl for rL1N.
Each of the expressed polypeptides was secreted into the medium
resulting in yields of more than 0.5 g/ml. N-terminal sequence anal-
ysis of the purified peptides using Edman degradation and amino acid
analysis confirmed the expected polypeptide sequence and also demon-
strated the purity of the peptides. SDS-PAGE analysis under nonre-
ducing and reducing conditions revealed that the LTBP-1, LTBP-3, and
LTBP-4 recombinant polypeptides were secreted as monomers from 293
cells (Fig. 2).
Antibodies and Immunoassays—Mouse monoclonal antibodies 201
and 69 to fibrillin-1 have been characterized previously (1, 13, 15, 38).
Polyclonal anti-fibrillin-1 9543 was also characterized (18, 22). Mono-
clonal antibodies, 75G, and 42E, were generated using full-length
LTBP-1 expressed by Sf9 insect cells (25). Mouse monoclonal antibody
246 against the TGF-1 propeptide, known as the LAP, was purchased
from R & D Systems (Minneapolis, MN), and rabbit polyclonal antibody
39 against human LTBP-1 was purchased from BD Pharmingen.
The specificity of monoclonal antibodies was determined by ELISA,
as described (41). Recombinant fibrillin-1 subdomains, rF11 and rF6,
and LTBP-1 subdomains, rL1N, rL1M, and rL1C, were used to coat
microtiter plates at 10 g/ml. The antibodies were diluted in TBS. For
Western blot analysis, serum-free conditioned medium from normal
skin fibroblasts was collected for 48 h (13). Proteins in the medium were
precipitated, subjected to 7.5% SDS-PAGE, and analyzed by immuno-
blotting as previously described (42).
Extraction and Size Fractionation of LTBP-1 from Tissues—Extracts
of normal adult human skin, bovine calf tendon, and human fetal
membranes were prepared as follows. Nonexposed human skin (1 g)
was obtained as excess tissue from a skin grafting procedure. Bovine
tendon (1.5 g) was dissected from an 80-cm crown to rump fetal calf
(245 days gestation, almost full-term) obtained from a local slaugh-
terhouse. A 40-ml suspension of fetal membranes, washed and homog-
enized as described (42), was also extracted as follows.
Tissue samples were minced, and the pellets were washed briefly
with 50 mM Tris-HCl, pH 7.5, containing 10 mM CaCl2, and 1 mM
phenylmethylsulfonyl fluoride. The buffer was removed after centrifu-
gation, and the pellet was extracted in 6 M guanidine hydrochloride, 50
mM Tris-HCl, pH 7.5, containing 1 mM phenylmethylsulfonyl fluoride
for 72 h at 4 °C with vigorous shaking. The supernatant was collected
after centrifugation, and the pellet was extracted in the same buffer for
48 h followed by centrifugation and another 24 h of extraction. The
supernatants were pooled and concentrated to 5 ml using an Amicon
concentrator (cut-off Mr  30,000). Sieve chromatography under disso-
ciative conditions was performed using a Sepharose CL-2B (Amersham
Biosciences) molecular sizing column (90-ml total volume), equilibrated
in 4 M guanidine HCl, 50 mM Tris-HCl, pH 7.5, at a flow rate of 0.1
ml/min. The fractions were collected every 2 ml. Protein concentrations
were determined using a BCA protein assay kit (Pierce) with bovine
serum albumin as the standard. Dot blot analysis was performed using
2.5 l of spotted fractions and either polyclonal antibody 39 or mono-
clonal antibodies 69, 75G, and 42E, as described (42). Western blot
analysis was performed using two combined consecutive fractions. Gua-
nidine hydrochloride was eliminated by ethanol precipitation as de-
scribed (43).
Microfibrils were also isolated from tissues using crude collagenase
(Sigma) digestion. Procedures used were the same as those we have
previously detailed (42).
Immunolocalization Studies—Light and electron microscopic immu-
nohistochemical procedures were the same as those we have previously
described (44). Tissues were frozen in hexanes for light and confocal
microscopy. Fluorescein isothiocyanate-conjugated rabbit anti-mouse
IgG (Sigma) was used for immunofluorescence microscopy, using 8-m
sections. For confocal microscopy, 25-m sections were incubated with
primary antibodies, followed by Alexa Fluor 488 goat anti-mouse IgG or
Alexa Fluor 594 goat anti-rabbit IgG (Molecular Probes, Eugene, OR).
Stained sections were viewed with a Leica TCS SP2 confocal microscope
and merged images were generated using Leica software. For electron
microscopic immunolocalization, fresh tissue blocks were first incu-
bated with dilutions of primary antibody, followed by a gold-conjugated
second antibody, and then embedded and prepared for electron
microscopy.
Binding Studies—Interactions between LTBP and fibrillin were in-
vestigated by solid phase ELISA binding or blot overlay assays. For
ELISA binding assays, multiwell plates were coated with purified
LTBP-1 peptides (50 nM, 100 l/well) in 15 mM Na2CO3 and 35 mM
NaHCO3, pH 9.2, at 4 °C overnight. Coated wells were blocked with 5%
nonfat dry milk in TBS at room temperature for 1 h. Recombinant
fibrillin-1 polypeptides were serially diluted 1:2 in 2% milk, TBS, con-
taining 2 mM CaCl2 or 5 mM EDTA, and incubated in the wells for 3 h.
Monoclonal antibodies against soluble ligands were diluted in 2% milk,
TBS and used to detect the bound ligands, after a final incubation with
enzyme-conjugated secondary antibodies. Color reaction of the enzyme
immunoassay was achieved using p-nitrophenyl phosphate (Sigma tab-
lets) or 1 mg/ml 5-aminosalicylic acid. Absorbance was determined at
405 nm using a Titertek Multiskan.
For blot overlay assays, serum-free conditioned media was collected
from High FiveTM cells that were transfected with recombinant
LTBP-1. 1 ml of media was precipitated using trichloroacetic acid,
resolved by SDS-PAGE, and transferred to a nitrocellulose membrane.
After blocking with 5% nonfat milk in TBS at room temperature for 1 h,
the membrane was incubated with recombinant fibrillin peptides (50
g/ml or 1 M) in 2% nonfat milk in TBS at 4 °C overnight or room
temperature for 3 h. Monoclonal antibodies diluted in 2% milk, TBS
were used to detect the bound ligands, after a final incubation with
enzyme-conjugated secondary antibodies. The blots were developed by
color reaction using 4-chloro-1-naphthol (Bio-Rad).
RESULTS
LTBP-1 and Fibrillin-1 Are Co-distributed in Some Tissues—
Although immunolocalization studies of LTBP-1 have been per-
formed using cultured cells and tissues, surveys of tissue dis-
tribution have not been published. In addition, most published
results have relied upon polyclonal antiserum 39. To immuno-
localize LTBP-1 with greater confidence and to establish tissue
distribution patterns, monoclonal antibodies were generated
using purified full-length recombinant human LTBP-1 ex-
pressed in insect cells. Two monoclonal antibodies (mAb 75G
and mAb 42E), which immunoblotted and immunoprecipitated
LTBP-1 produced by insect cells (data not shown), were se-
lected for further characterization. Epitopes for these antibod-
ies were mapped by immunoblotting using four LTBP-1 recom-
binant polypeptides (Fig. 1A) expressed in 293 human
embryonic kidney cells. MAb 75G recognized an epitope in
rL1M, but did not bind to rL1N or rL1C (data not shown). mAb
42E bound to a site close to the C-terminal region in rL1C, not
in rL1K (data not shown). In addition, mAb 75G and mAb 42E
recognized authentic LTBP-1 present in the medium of cul-
tured human fibroblasts (NSF lane, in Fig. 7). 75G and 42E
displayed no reactivity with authentic fibrillin in fibroblast-
conditioned medium, nor with rF11 and rF6, the two recombi-
nant halves of fibrillin-1 (data not shown).
When tested using a panel of human tissues, mAb 75G and
FIG. 2. Coomassie Blue-stained gels of recombinant LTBP-1
polypeptides used in these investigations. A, full-length LTBP-1
protein present in conditioned insect cell medium. LTBP-1 was identi-
fied by immunoblotting (data not shown). This sample, run without
disulfide bond reducing agent, was used for blot overlay experiments. B,
purified recombinant LTBP-1, LTBP-3, and LTBP-4 polypeptides. Sam-
ples were run on SDS-PAGE without reducing agent.
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mAb 42E yielded similar immunohistochemical results. In tis-
sues such as tendon, perichondrium, and blood vessels, the
staining patterns for LTBP-1 and fibrillin-1 were apparently
identical. In tendon and perichondrium, long fluorescent fibrils
were evident after staining with anti-LTBP-1 (Fig. 3, A and L)
or with anti-fibrillin-1 (Fig. 3B). Matrix around blood vessels
was densely stained with antibodies to LTBP-1 (arrowheads in
Fig. 3, C, K, and L) and fibrillin-1 (Fig. 3D). However, in other
tissues such as skeletal muscle (Fig. 3, I compared with J) and
lung (Fig. 3, C compared with D) where fibrillin-1 was abun-
dant, LTBP-1 appeared to be absent or more limited in spatial
distribution. In lung, bright staining for LTBP-1 was found
around blood vessels but faint staining outlined the airways
(Fig. 3C, arrow). In peripheral nerves, LTBP-1 appeared to be
present primarily in the outer nerve sheath (Fig. 3, E and L,
asterisks), whereas fibrillin-1 was found in all three connective
tissue sheaths of the nerve (Fig. 3F). In skin, fibrillin-1 was
present throughout the dermis (Fig. 3H), whereas LTBP-1 was
much less abundant and was concentrated primarily in hair
follicles (Fig. 3G) and scattered fibers (Fig. 3K).
These studies demonstrated that LTBP-1 is not present in all
tissues containing fibrillin microfibrils. Co-distribution of
LTBP-1 and fibrillin was prominent in tendon, perichondrium,
cartilage, and all blood vessels. Partial co-distribution was
found in tissues like skin, lung, and peripheral nerve.
Confocal and Electron Microscopic Immunolocalization Dem-
onstrate Colocalization of Fibrillin-1 and LTBP-1—Tissues
demonstrating strong LTBP-1 immunofluorescence were cho-
sen for additional analyses to determine whether LTBP-1 and
fibrillin-1 are colocalized. In the developing fetal foot, tendons
were well labeled with LTBP-1 antibodies (Fig. 4A) and fibril-
lin-1 antibodies (Fig. 4B). The merged image (Fig. 4C) indicated
that in the tendon most of the fibrillar staining directed by
LTBP-1 antibodies was labeling the same fibrillar structures
that were stained by fibrillin-1 antibodies.
In addition, neonatal foreskin, fetal bovine tendon, and fetal
bovine aorta were immunolabeled with anti-LTBP-1 mAb 75G
and examined by electron microscopy. As has been reported,
immunogold labeling was observed on microfibrils (Fig. 5, A
and C). However, in contrast to the periodic labeling obtained
with antibodies to fibrillin-1 (1, 15) (Fig. 5B) and with poly-
clonal antibodies to LTBP-1 (30), LTBP-1 antibody-directed
gold labeling was sparse and irregular (Fig. 5, A and C).
Microfibril Extracts from Tissues Do Not Contain LTBP-
1—To determine whether LTBP-1 is contained within microfi-
brils or is a microfibril-associated molecule, extraction studies
were performed. Bovine calf tendon, human fetal membranes
(data not shown), and human skin, tissues in which LTBP-1
co-localizes with fibrillin, were used. Microfibrils were ex-
tracted either by crude collagenase digestion or denaturation in
guanidine HCl. After fractionation using Sepharose CL-2B
chromatography, fibrillin microfibrils were eluted in the void
volume fraction both from the collagenase digests (human fetal
membranes and human skin) and the guanidine HCl extracts
(human fetal membranes and fetal bovine tendon), as shown by
dot blot analysis with several anti-fibrillin-1 antibodies and
rotary shadowing (Fig. 6 and data not shown). Interestingly, no
immunoreactivity with LTBP-1 antibodies (mAb 75G, mAb
42E, or pAb 39) was detected in the microfibril fractions from
any of the tissues examined, including collagenase and guani-
dine extracts of human skin and bovine tendon (Figs. 6 and 7)
and collagenase and guanidine extracts of human fetal mem-
branes (data not shown). These results suggested that LTBP-1
is not an integral structural component of the beaded string
microfibril.
When LTBP-1 was extracted from tendon and skin using
guanidine HCl, Western and dot blots using mAb 75G (data not
shown), mAb 42E and pAb 39 (data not shown) detected
LTBP-1 in the included fractions of the Sepharose CL-2B col-
umn with a molecular mass close to 200 kDa (Fig. 7). This
molecular mass, similar to that of authentic LTBP-1 found in
normal skin fibroblasts (NSF lane, in Fig. 7), corresponds to the
FIG. 4. Colocalization of LTBP-1
and fibrillin-1 in tendon. Confocal mi-
croscopy using LTBP-1 mAb 75G (A) and
fibrillin-1 pAb 9543 (B) demonstrated co-
localization of LTBP-1 and fibrillin-1 (C)
in tendon of a 15-week fetal human foot
specimen. Bar  80 m.
FIG. 3. Immunofluorescence stain-
ing of tissues using antibodies spe-
cific for LTBP-1 (A, C, E, G, I, K, and
L) and fibrillin-1 (B, D, F, H, and J).
Sections in C and D were 20-week human
fetal lung, and sections in K and L were
from an 8-year-old human toe. A (tendon),
B (perichondrium), E and F (peripheral
nerve), G and H (skin), and I and J (skel-
etal muscle) were 16-week human fetal
tissues. The arrow in C indicates LTBP-1
staining around an airway. Arrowheads
in C, K, and L point to blood vessels, and
asterisks in L designate peripheral
nerves. Bar  50 m.
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complex of LTBP and LAP (25). Indeed, in human skin ex-
tracts, LTBP-1 was detected as a complex with LAP (Fig. 7B).
The small apparent differences in molecular masses of the
LTBP-1 complexes from these two tissues may reflect either
the presence of differentially spliced isoforms or proteolytic
degradation in the case of skin.
LTBP-1 Binds to Fibrillins—Blot overlay assays were uti-
lized to screen for regions of fibrillins that might interact with
LTBP-1. Insect cell-conditioned medium containing full-length
recombinant human LTBP-1 (and multiple other proteins) (Fig.
2A) was subjected to SDS-PAGE, transferred to nitrocellulose,
and used as substrate for the binding assays. Recombinant
human fibrillin-1 and fibrillin-2 polypeptides (Fig. 1B) were
purified and used as ligands for these assays. Detection of
bound ligands was accomplished by using specific mAbs to
fibrillins or by using a monoclonal antibody that reacts with the
FIG. 5. Immunolocalization of LTBP-1. MAb 75G, followed by
immunogold-labeled microfibril bundles in neonate skin (A) as well as
elastic fiber microfibrils in fetal bovine aorta (C). The middle panel (B)
demonstrates typical periodic labeling of microfibrils in neonate skin
using anti-fibrillin-1 mAb 69. Bars  100 nm.
FIG. 6. Analyses of collagenase-digested microfibrils from hu-
man skin. A, Sepharose CL-2B chromatograph, indicating the elution
position of beaded strings of microfibrils, identified by rotary shadowing
electron microscopy. B, dot blot analysis demonstrated the presence of
fibrillin-1 (mAb 69) in the microfibril fractions but not in subsequent
fractions; dot blot analyses of the same fractions with mAb 75G and pAb
39 failed to detect LTBP-1 in the microfibril fractions, but revealed
LTBP-1 in subsequent fractions. Each row contains replicate dotted
samples from the microfibril fractions through the later eluting peak.
FIG. 7. Analyses of guanidine HCl extracted tissues. A, Sepha-
rose CL-2B chromatography of extract from fetal bovine tendon fol-
lowed by Western blotting of fractions revealed LTBP-1 in fractions
28–44 but not in the earlier microfibril containing fractions (16–20). B,
Sepharose CL-2B chromatography of human skin followed by Western
blotting of fractions revealed both LAP and LTBP-1 in fractions 32–40.
Each fraction contains 2 ml (fractions 32–40 are equivalent to 64–80 ml
of elution volume). Gels were run without reducing agent. Partially
purified authentic LTBP-1 from fibroblast cell culture medium (NSF)
was applied as a control and to demonstrate molecular mobility in these
gels. V0 and Vt are the same for A and B.
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histidine tag present at the C-terminal end of some fibrillin
recombinant polypeptides. When the large N- and C-terminal
halves of fibrillin-1 (rF11 and rF6, respectively) were tested, rF11
bound to LTBP-1 but rF6 did not (Fig. 8A). When subregions of
rF11 were tested, rF23 and rF38 were positive, whereas other
regions of rF11 (rF20 and rF31) were negative (Fig. 8A). These
data localized the binding site in fibrillin-1 to the four domains
contained in rF38 (see Fig. 1B). When fibrillin-2 recombinant
polypeptides were used as ligands, rF37 and rF46 interacted
with LTBP-1 (Fig. 8B), suggesting that the homologous region of
fibrillin-2 was also capable of binding to LTBP-1.
To define the binding site in LTBP-1, recombinant LTBP-1
polypeptides, rL1N, rL1M, rL1C, and rL1K were tested in both
blot overlay (data not shown) and ELISA. Results indicated that
the major binding site for fibrillin-1 is contained in the
C-terminal region of LTBP-1, rL1C (Fig. 9A). A small subdomain
of rL1C, rL1K, contained the fibrillin-1 binding site (Fig. 9B).
When ELISAs were performed to compare the binding of fibril-
lin-1 and fibrillin-2 with LTBP-1, fibrillin-1 polypeptides dis-
played much higher affinities for LTBP-1 than fibrillin-2
polypeptides (Fig. 9A). Incubation of ligands in the presence of
EDTA did not affect the LTBP-1/fibrillin interaction (data not
shown).
To test whether homologous regions of other LTBPs might
perform similar functions, recombinant LTBP-3 and LTBP-4
polypeptides were expressed and purified. In ELISA binding
assays, fibrillin ligands interacted equally well with rL1K and
rL4K, but not with rL3K (Fig. 9B). As observed for the binding to
rL1K, the same region of fibrillin-1 (rF23 but not rF31) contained
the binding site for rL4K (Fig. 9B). Additional studies that pre-
cisely define the binding site in LTBP-1 and LTBP-4 are required
to understand why these bind to fibrillin and LTBP-3 does not.
DISCUSSION
Beaded string structures have been extracted from various
tissues and shown by immunolabeling to contain periodically
spaced fibrillin molecules (14, 15). Together with the known
extended structure of fibrillin (13), these studies have sug-
gested that the strings connecting the globular beads in the
beaded microfibrils are fibrillin molecules. However, molecules
similar in shape to fibrillins may also constitute the string-like
connecting filaments in microfibrils. LTBPs are candidate mol-
ecules to be considered, because they have been immunolocal-
ized to microfibrils and because they are structurally homolo-
gous to fibrillins.
Procedures for extraction of microfibrils are now routinely
utilized (45, 46). These procedures rely upon crude collagenase
digestion of tissues to release microfibrils from the insoluble
FIG. 9. ELISA binding assays using recombinant LTBP-1
polypeptides and recombinant fibrillin ligands. A, fibrillin li-
gands bound preferentially to rL1C and demonstrated higher affinity of
fibrillin-1 (rF23) compared with fibrillin-2 (rF37). B, fibrillin-1 ligands
(rF11 and rF23, but not rF6) bound equally well to rL1K and rL4K, but
did not bind to rL3K.
FIG. 10. Proposed model of LTBP-1 in relation to fibrillin mi-
crofibrils and other extracellular matrix components. This model
is adapted from Ref. 24. The N-terminal end of LTBP-1 is transglutami-
nase cross-linked to the extracellular matrix. The small latent TGF-
complex is bound covalently to CR3 of LTBP-1. The numbers, 1 and 2,
mark protease-sensitive sites in LTBP-1. Interaction between LTBP-1
and fibrillin takes place between the C-terminal region of LTBP-1 and
the N-terminal region of fibrillin. Latent TGF- may be targeted and
sequestered by the interactions occurring at both the N-terminal and
C-terminal ends of LTBP-1.
FIG. 8. Blot overlay assays of immobilized recombinant full-
length LTBP-1 in insect cell medium (Fig. 2A) incubated with
fibrillin ligands and antibody probes. Control lanes, where soluble
ligand was omitted but antibody probe was incubated with the blot, are
identified with the antibody used for detection. A, recombinant fibril-
lin-1 ligands that bound to LTBP-1 included rF11 and subdomains rF23
and rF38. rF11 was detected with mAb 201. Detection of rF6 was with
mAb 69. Antihistidine was used to detect rF23, rF38, rF31, and rF20. B,
recombinant fibrillin-2 polypeptides rF37 and rF46, detected by mAb
161, also bound to LTBP-1.
LTBP/Fibrillin Interactions 2755
 at UQ Library on October 16, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
extracellular matrix environment. We have recently found that
highly purified bacterial collagenase does not release fibrillin
microfibrils from tissues, suggesting that microfibrils are not
simply trapped in the matrix by collagen fibers (42). Further
digestion with crude collagenase, which contains other pro-
teases, is required to release microfibrils. These results indi-
cate that molecules linking microfibrils to the insoluble extra-
cellular matrix must be degraded to release microfibrils. We
have demonstrated that versican is one of these molecules (42).
In the current investigations, we have shown that LTBP-1 is
not a component of crude collagenase-digested microfibrils.
Therefore, LTBP-1 is likely not to be a connecting string in
these microfibrils. Because LTBP-1, unlike fibrillins, contains
several regions of protein sequences that may provide sensitive
sites for proteolysis (47), LTBP-1 may have been degraded in
the digestion protocol. Hence, it is possible that LTBP-1 was
present in the collagenase-digested beaded microfibrils as de-
graded stubs but undetected with the available antibodies. To
address this possibility, microfibrils were extracted from tis-
sues using nondegradative procedures and fractionated by
sieve chromatography. Denaturing guanidine HCl extractions
released small amounts of microfibrils found in fractions that
failed to react with antibodies specific for LTBP-1. However,
LTBP-1 immunoreactive materials close to the size of com-
plexes containing full-length LTBP-1 and LAP were detected in
the guanidine extracts. Taken together, these data suggest that
LTBP-1 is not substantially cross-linked into the beaded string
microfibril structure and may not be an integral component of
microfibrils.
Results from immunoelectron microscopic analyses of tissues
are consistent with the conclusion that LTBP-1 may not be an
integral component of microfibrils. In the present studies, la-
beling of tissues with anti-LTBP-1 was always sparse and
never periodic. In contrast, immunolabeling of calvarial cell
cultures revealed some periodic labeling of microfibrils using
an anti-LTBP-1 serum (30). It may be that cells in culture can
secrete and deposit larger amounts of LTBP-1 into the extra-
cellular matrix than was observed in the tissues we sampled.
Because immunolocalization experiments indicated that
LTBP-1 is associated with microfibrils, binding studies were
conducted to determine whether LTBP-1 interacts with fibril-
lin. Binding was detected using well characterized recombinant
fibrillin polypeptides in blot overlay assays with either full-
length recombinant LTBP-1 or authentic LTBP-1 present in
fibroblast cell culture medium. ELISA binding studies demon-
strated that the interaction was not calcium-dependent and
that the interaction between fibrillin-1 and LTBP-1 appeared
to be much stronger than the interaction between fibrillin-2
and LTBP-1. These studies mapped the binding site for fibrillin
to the C-terminal region of LTBP-1, a region corresponding to
the domains contained in peptide rL1K. This result is consist-
ent with a study showing that the C-terminal region of LTBP-1
can associate with extracellular matrix in cell culture experi-
ments (48). The binding site for LTBP-1 in fibrillin-1 is con-
tained within four domains (rF38) close to the N-terminal end
of fibrillin-1. The homologous region of fibrillin-2 (rF46) may
also mediate binding to LTBP-1, but with lower affinity than
fibrillin-1.
Because LTBP-1 is similar in structure and function to other
LTBP family members, it seemed plausible that other LTBPs
might interact with fibrillins, using binding sites homologous
to rL1K. To test this hypothesis, recombinant polypeptides
were constructed for mouse LTBP-3 (rL3K) and human LTBP-4
(rL4K). Binding by fibrillin to the LTBP-4 polypeptide was
strong, equivalent to the interaction with LTBP-1, and specif-
ically mediated by the same region in fibrillin. However, the
comparable C-terminal region of LTBP-3 did not appear to bind
to the N-terminal region of fibrillin-1 (rF23), suggesting that
LTBP-3 may specifically bind to other sites in fibrillins or to
another fibrillin, that it uses other domains to mediate inter-
actions with fibrillins, or that it does not interact with fibril-
lins. Immunolocalization of LTBP-3 and LTBP-4 to microfibrils
in tissues has not yet been performed.
Based on these findings, we propose a model of LTBP-1 in
association with the extracellular matrix and with fibrillin
networks (Fig. 10). The N-terminal region of LTBP-1 is cross-
linked to the extracellular matrix (28). In our investigations,
the N-terminal third of LTBP-1 (rL1N) did not display any
binding to fibrillin-1 or fibrillin-2. Therefore, it is likely that the
N-terminal region of LTBP-1 is cross-linked to components
other than fibrillins. We cannot, however, exclude that the
N-terminal region of LTBP-1 interacts with components of
microfibrils other than the fibrillins. Because our studies of
extracted microfibrils did not demonstrate the presence of
LTBP-1 in the beaded strings, we suggest that the N-terminal
region of LTBP-1 is associated with matrix molecules close to
microfibrils, but not present within the beaded microfibril.
Networks such as the one depicted in Fig. 10 can be modified
in vivo in a tissue-specific manner. LTBPs may be present in
different tissues, as shown for LTBP-1 in this investigation.
Fibrillins are also present in tissues in differential temporal
and spatial patterns. Additional information regarding tissue
distributions of the fibrillins and the LTBPs is required. How-
ever, we can speculate that in skeletal muscle, for example,
fibrillin-1 may interact with LTBP-4, because LTBP-1 is not
present in this tissue and LTBP-4 is highly expressed in skel-
etal muscle (11). In the developing and postnatal lung, fibril-
lin-1 may interact with LTBP-1 in blood vessels and cartilage
and with LTBP-1 and LTBP-4 in the airways.
Based upon our findings, we propose that interactions be-
tween LTBP-1 and fibrillin-1 may stabilize latent TGF- com-
plexes in the extracellular matrix. It is possible that loss of
fibrillin-1 would abolish this stabilization and lead to activa-
tion of TGF-. Activation of TGF- was recently demonstrated
in the lungs of fibrillin-1-deficient mice.3 In Marfan syndrome,
caused by mutations in fibrillin-1, loss of fibrillin-1 microfibrils
leads to multiple phenotypic features that may result in part
from activation of TGF-. This hypothesis will be tested in
future investigations.
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